Aurus Capital

Aurus Capital is a Santiago-based VC and one of the few regional Latin American firms with a genuine history of life sciences and biotech investment. The firm writes Series A and Series B checks in the $1M to $5M range, with healthcare interest spanning biotech, medical devices, and pharmaceuticals and therapeutics. Aurus is not positioned as an AI-native specialist; the lens is fundamentally science and life-sciences-driven, which is unusual in a regional landscape dominated by digital health and consumer technology investors. The geographic focus is Chile with selective Latin American expansion, and the firm’s relationships across the Chilean academic and industrial ecosystem give it sourcing depth in life sciences that competing regional VCs lack. The right founder profile is a Chilean or Latin American science-driven founder building a biotech, medical device, or therapeutic platform with credible R&D progress, ideally with academic anchoring and a clear regulatory pathway. The wrong fit is a B2C wellness brand, a workflow software platform, or a consumer health business; Aurus’s pattern recognition is concentrated in science and life sciences. The right entry path is through Santiago academic and research networks, particularly PUC and Universidad de Chile, through Corfo-backed grant and accelerator programs that frequently surface Aurus-relevant deals, through warm introductions from co-investors and from the Latin American life sciences operator community, and through international biotech investor networks that track Latin American opportunities. When pitching, lead with the science, the technical moat, the experimental validation, and the regulatory pathway, then connect to the commercial trajectory and the global market opportunity that justifies the patient capital required. Caveats: Aurus is a relatively small fund operating in a regional ecosystem with limited follow-on biotech capital, so founders should plan their syndicate carefully and prepare for international biotech investors at Series B and beyond. The Chilean macro environment also affects how founders structure capital, and dollar-denominated rounds with offshore holding structures are increasingly the norm. Use Aurus as the rare Latin American life sciences specialist partner that gives your science-driven Chilean company genuine credibility for international capital later.